DK1263752T3 - LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf - Google Patents
LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse herafInfo
- Publication number
- DK1263752T3 DK1263752T3 DK01922465T DK01922465T DK1263752T3 DK 1263752 T3 DK1263752 T3 DK 1263752T3 DK 01922465 T DK01922465 T DK 01922465T DK 01922465 T DK01922465 T DK 01922465T DK 1263752 T3 DK1263752 T3 DK 1263752T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- antagonists
- lpa
- lpa receptor
- activity
- Prior art date
Links
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title abstract 4
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title abstract 4
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/4028—Esters of poly(thio)phosphonic acids containing no further substituents than -PO3H2 groups in free or esterified form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/098—Esters of polyphosphoric acids or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/17—Esters of thiophosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19037000P | 2000-03-17 | 2000-03-17 | |
| PCT/US2001/008729 WO2001071022A2 (en) | 2000-03-17 | 2001-03-19 | Lpa receptor agonists and antagonists and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1263752T3 true DK1263752T3 (da) | 2008-04-14 |
Family
ID=22701059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01922465T DK1263752T3 (da) | 2000-03-17 | 2001-03-19 | LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6875757B2 (https=) |
| EP (2) | EP1263752B1 (https=) |
| JP (1) | JP2004506604A (https=) |
| KR (1) | KR100874392B1 (https=) |
| AT (1) | ATE380187T1 (https=) |
| AU (1) | AU4926301A (https=) |
| CA (1) | CA2402038C (https=) |
| CY (1) | CY1107214T1 (https=) |
| DE (1) | DE60131730T2 (https=) |
| DK (1) | DK1263752T3 (https=) |
| ES (1) | ES2298227T3 (https=) |
| PT (1) | PT1263752E (https=) |
| WO (1) | WO2001071022A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030130237A1 (en) * | 2000-03-17 | 2003-07-10 | Miller Duane D. | LPA receptor agonists and antagonists and methods of use |
| DK1263752T3 (da) * | 2000-03-17 | 2008-04-14 | Univ Tennessee Res Corp | LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf |
| EP1361872A4 (en) | 2000-10-03 | 2004-05-19 | Univ Virginia | NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS |
| US7064217B2 (en) | 2001-01-30 | 2006-06-20 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| ES2312588T3 (es) * | 2001-07-17 | 2009-03-01 | Ono Pharmaceutical Co., Ltd. | Regulacion de la secrecion del jugo pancreatico que comprende un agente de regulacion del receptor del lpa. |
| WO2003068931A2 (en) * | 2002-02-13 | 2003-08-21 | The Scripps Research Institute | Purification of the leading front migratory cells |
| AU2003241833A1 (en) * | 2002-05-28 | 2003-12-12 | Ono Pharmaceutical Co., Ltd. | Beta-ALANINE DERIVATIVE AND USE THEREOF |
| DE10225651A1 (de) * | 2002-06-08 | 2003-12-24 | Aventis Pharma Gmbh | Verfahren zur Identifizierung von Agonisten oder Antagonisten für den GPR45like/GPR63 Rezeptor |
| US7300764B2 (en) | 2002-06-08 | 2007-11-27 | Sanofi-Aventis Deutschland Gmbh | Method for identifying agonists and antagonists of the GPR45-like/GPR63 receptor |
| EP1550461A1 (en) | 2002-06-26 | 2005-07-06 | Ono Pharmaceutical Co., Ltd. | Remedy for chronic disease |
| CA2533587A1 (en) * | 2002-07-30 | 2004-02-05 | University Of Virginia Patent Foundation | Compounds active in sphingosine 1-phosphate signaling |
| AU2003276221A1 (en) * | 2002-11-13 | 2004-06-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with endothelial differentiation, sphingolipid g-protein-coupled receptor 4 (edg4) |
| EP1579866A4 (en) * | 2002-12-12 | 2009-07-29 | Takeda Pharmaceutical | NEW USE OF EDG RECEPTORS |
| US7524638B1 (en) * | 2003-06-27 | 2009-04-28 | Osi Pharmaceuticals, Inc. | Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease |
| WO2005009469A1 (ja) * | 2003-07-28 | 2005-02-03 | Sumitomo Pharmaceuticals Co., Ltd. | 新規血糖調節薬及びそのスクリーニング方法 |
| EP2433946B1 (en) * | 2003-10-09 | 2016-04-20 | University of Tennessee Research Foundation | LPA receptor agonists and antagonists and methods of use |
| WO2005041899A2 (en) * | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
| US7820703B2 (en) | 2004-05-06 | 2010-10-26 | University Of Virginia Patent Foundation | Lysophosphatidic acid receptor selective antagonists |
| US20060223866A1 (en) * | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
| MX2007001661A (es) * | 2004-08-13 | 2007-04-23 | Praecis Pharm Inc | Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip). |
| JP2008522977A (ja) * | 2004-12-06 | 2008-07-03 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン＝１−リン酸のアリールアミドアナログ |
| AU2006214314B2 (en) | 2005-02-14 | 2012-02-09 | University Of Virginia Patent Foundation | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
| US20070078111A1 (en) | 2005-07-19 | 2007-04-05 | Gabor Tigyi | LPA2 receptor agonist inhibitors of CFTR |
| KR20080086546A (ko) * | 2006-01-27 | 2008-09-25 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 신경병증성 통증의 치료 방법 |
| AU2007212193A1 (en) * | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
| CA2669102A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
| AU2007323557A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| CA2669104A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| CA2686735A1 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
| CN101358609A (zh) * | 2007-08-03 | 2009-02-04 | 富准精密工业(深圳)有限公司 | 风扇转子 |
| JP5692746B2 (ja) * | 2008-08-07 | 2015-04-01 | 国立大学法人 長崎大学 | 全身性疼痛症候群の治療または予防薬 |
| US9034820B2 (en) | 2011-03-14 | 2015-05-19 | Hsinyu Lee | Method and composition for modulating erythropoiesis |
| HK1199259A1 (en) | 2011-08-15 | 2015-06-26 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| EP2858635A1 (en) * | 2012-06-11 | 2015-04-15 | The Regents of The University of California | Inhibitors of hippo-yap signaling pathway |
| CA2935677C (en) * | 2013-12-30 | 2022-07-26 | Rama Krishna Reddy SINGIDI | Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB861463A (en) | 1957-05-03 | 1961-02-22 | Ciba Ltd | Process for the manufacture of phosphoric acid esters and piperazine and morpholine derivatives |
| US3639571A (en) * | 1970-01-29 | 1972-02-01 | Samuel Turesky | Composition and method for retarding plaque and dental calculus |
| JPS5687590A (en) * | 1979-12-19 | 1981-07-16 | Yoshitomi Pharmaceut Ind Ltd | Diphosphoglycerine derivative |
| JPS59104310A (ja) * | 1982-12-07 | 1984-06-16 | Lion Corp | 口腔用組成物 |
| US4670575A (en) * | 1984-06-05 | 1987-06-02 | Kao Corporation | Process for purification of phosphoric mono esters |
| EP0340759A1 (en) * | 1988-05-06 | 1989-11-08 | MAGIS FARMACEUTICI S.p.A. | Salts of O-mono (di)-acetyl-glycero-mono-(bis)-(di)-phosphates of L-acetyl-carnitine and of L-acetyl carnitine esters |
| WO1990010014A1 (fr) | 1989-02-28 | 1990-09-07 | Teijin Limited | Nouveau derive de vitamine b12, sa production et son application |
| JPH02250892A (ja) | 1989-03-24 | 1990-10-08 | Idemitsu Kosan Co Ltd | 新規フェロセン誘導体，それを含有する界面活性剤及び有機薄膜の製造方法 |
| CA2072249C (en) * | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US5565439A (en) | 1992-11-24 | 1996-10-15 | The Procter & Gamble Company | Methods of using lysophosphatidic acid for treating hyperproliferative conditions |
| WO1994023748A1 (en) | 1993-04-08 | 1994-10-27 | The University Of Queensland | Administration of vaso-active agent and therapeutic agent |
| US5480877A (en) | 1993-11-02 | 1996-01-02 | Wisconsin Alumni Research Foundation | Use of lysophosphatidic acids to enhance fibronectin binding |
| GB9618634D0 (en) * | 1996-09-06 | 1996-10-16 | Univ Southampton | Anti cancer drugs |
| EP1024812B1 (en) | 1997-03-19 | 2007-01-24 | Sky High, LLC | Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof |
| CA2301921A1 (en) | 1997-08-20 | 1999-02-25 | John Graham Goddard | Compositions containing polyethylene glycol and uses thereof |
| US5945522A (en) * | 1997-12-22 | 1999-08-31 | Genset | Prostate cancer gene |
| AU3191599A (en) * | 1998-03-18 | 1999-10-11 | Lxr Biotechnology Inc. | Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof |
| DK1263752T3 (da) * | 2000-03-17 | 2008-04-14 | Univ Tennessee Res Corp | LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf |
-
2001
- 2001-03-19 DK DK01922465T patent/DK1263752T3/da active
- 2001-03-19 AT AT01922465T patent/ATE380187T1/de not_active IP Right Cessation
- 2001-03-19 CA CA2402038A patent/CA2402038C/en not_active Expired - Fee Related
- 2001-03-19 US US09/811,838 patent/US6875757B2/en not_active Expired - Fee Related
- 2001-03-19 EP EP01922465A patent/EP1263752B1/en not_active Expired - Lifetime
- 2001-03-19 DE DE60131730T patent/DE60131730T2/de not_active Expired - Lifetime
- 2001-03-19 KR KR1020027012236A patent/KR100874392B1/ko not_active Expired - Fee Related
- 2001-03-19 AU AU4926301A patent/AU4926301A/xx not_active Withdrawn
- 2001-03-19 WO PCT/US2001/008729 patent/WO2001071022A2/en not_active Ceased
- 2001-03-19 JP JP2001569403A patent/JP2004506604A/ja active Pending
- 2001-03-19 ES ES01922465T patent/ES2298227T3/es not_active Expired - Lifetime
- 2001-03-19 EP EP07122187A patent/EP1918287A3/en not_active Withdrawn
- 2001-03-19 PT PT01922465T patent/PT1263752E/pt unknown
-
2005
- 2005-02-28 US US11/067,884 patent/US20050261252A1/en not_active Abandoned
-
2008
- 2008-02-26 CY CY20081100222T patent/CY1107214T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE380187T1 (de) | 2007-12-15 |
| AU4926301A (en) | 2001-10-03 |
| EP1263752A4 (en) | 2003-07-30 |
| CA2402038C (en) | 2011-03-15 |
| PT1263752E (pt) | 2008-03-18 |
| JP2004506604A (ja) | 2004-03-04 |
| EP1263752B1 (en) | 2007-12-05 |
| US6875757B2 (en) | 2005-04-05 |
| DE60131730T2 (de) | 2008-11-20 |
| EP1918287A2 (en) | 2008-05-07 |
| US20030027800A1 (en) | 2003-02-06 |
| KR100874392B1 (ko) | 2008-12-17 |
| WO2001071022A2 (en) | 2001-09-27 |
| CA2402038A1 (en) | 2001-09-27 |
| DE60131730D1 (de) | 2008-01-17 |
| EP1918287A3 (en) | 2008-08-20 |
| KR20020082890A (ko) | 2002-10-31 |
| ES2298227T3 (es) | 2008-05-16 |
| CY1107214T1 (el) | 2012-11-21 |
| EP1263752A2 (en) | 2002-12-11 |
| US20050261252A1 (en) | 2005-11-24 |
| WO2001071022A3 (en) | 2002-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1263752T3 (da) | LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf | |
| IL185871A0 (en) | N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor | |
| ATE349434T1 (de) | Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten | |
| ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| DK1678096T3 (da) | LPA-receptoragonister og -antagonister og anvendelsesfremgangsmåder | |
| ATE324371T1 (de) | N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| DE60329030D1 (de) | Melanocortin-rezeptormodulatoren | |
| ATE299494T1 (de) | Carbamat-derivate als muscarin-rezeptor antonisten | |
| BR0213010A (pt) | Aminopirimidinas substituìdas com tiazolila como agentes de proteção de plantas | |
| BR0215360A (pt) | Derivados de indolina úteis como inibidores de proteìna quinase | |
| ES2243579T3 (es) | Derivados de pirazolopirideno. | |
| BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| DE69935670D1 (de) | Behandlung von dyskinesie durch mu-selektive opioidantagonisten | |
| DK1456212T3 (da) | 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse | |
| DK1673354T3 (da) | Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister | |
| AP2001002188A0 (en) | 5HT1 antagonists for antidepressant therapy. | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| ATE373000T1 (de) | Pyrazolopyridin-derivate als antiherpesmittel | |
| DK1273572T3 (da) | Thiophensubstituerede piperaziner anvendelige til behandling af binign prostatisk hyperplasi | |
| WO2003024402A3 (en) | Lpa receptor agonists and antagonists and methods of use | |
| BR0317377A (pt) | Derivados de 5-aminofenantridina como antagonistas de npy-5 |